🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchAnyone else refreshing ClinicalTrials.gov every morning or just me

Anyone else refreshing ClinicalTrials.gov every morning or just me

TrialNerd_Beth Thu, Apr 30, 2026 at 8:30 AM 22 replies 944 viewsPage 1 of 5
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Apr 30, 2026 at 8:30 AM#1

My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my material.

So the question, as narrowly as I can put it: how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

I would rather have one careful answer than five confident ones.

13 16RickReta_CO, PharmHunterJen, TomTeleRx and 10 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Apr 30, 2026 at 8:45 AM#2

This one has a reasonably settled answer, so here it is. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.

Happy to go further on any of that.

14 17dave_SLC, FDA_TrackerJim, ricardo_MIA and 11 others
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Apr 30, 2026 at 9:00 AM#3
PeptideChemSF said:
Relative and absolute effects need reading together.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

15 18adam_van, Dr.SurgeonPGH, rachel_ABQ and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Apr 30, 2026 at 9:15 AM#4
TrialNerd_Beth said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Same position here, arrived at the long way round. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

Last edited: Apr 30, 2026 at 12:15 PM
16 19FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 13 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Apr 30, 2026 at 10:33 AM#5

From the other side of the consultation, briefly.

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.81 (95% CI 0.67-0.86), I²=54%. This is a robust and consistent effect.

17 20mike_nyc, VendorMark, COA_Karl and 14 others
Reply Quote Save Share Report
1235

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register